Binex Co Ltd

Binex Co Ltd's capital structure shows a debt-to-equity ratio of 0.52, indicating moderate leverage relative to its equity base. However, the company's liquidity position is concerning, with negative cash and equivalents of -1.74 billion KRW and a negative operating cash flow of -23.27 billion KRW. The current ratio of 1.8 suggests the company can cover its short-term liabilities, but the negative free cash flow of -12.38 billion KRW highlights ongoing cash generation challenges.

Profitability metrics are weak, with a return on equity of -1.72% and a return on assets of -1.04%, both significantly below the industry median for pharmaceutical firms. The company reported a net loss of 3.23 billion KRW and an operating loss of 4.53 billion KRW, indicating a failure to generate sustainable earnings from core operations.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to market-specific risks, particularly in the South Korean healthcare market.

Looking ahead, the company's growth trajectory is uncertain. Revenue for the latest period was 168.47 billion KRW, but no specific growth rate or outlook is provided in the available data. Analysts have assigned a mean price target of 22,100 KRW, with a median of 21,500 KRW, but the absence of positive earnings and cash flow raises questions about the sustainability of any upward movement.

Risk factors include liquidity constraints, with negative net cash after subtracting total debt, and the potential for further operating losses to strain working capital. The company's dilution risk is currently assessed as low, but the absence of positive free cash flow and the need for capital expenditures of 23.26 billion KRW could necessitate future equity or debt financing.

Recent events include the publication of the latest financial results, which show deteriorating profitability and liquidity. No material regulatory or litigation events are disclosed in the available data, but the company's operating losses and negative cash flows suggest ongoing operational challenges.